NEW YORK (GenomeWeb News) – SynapDx this week said that it has received a "significant investment" from The Kraft Group that will support ongoing clinical development of its molecular diagnostic test for autism spectrum disorder. Lexington, Mass.-based SynapDx didn't disclose the amount of the funding from Kraft.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

In Genome Biology this week: miRNAs linked to diffuse large B-cell lymphoma outcomes, database of bird genomes, and more.